{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=44", "query": { "condition": "Metastatic Solid Tumor Cancers", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 1754, "total_pages": 176, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T00:13:13.024Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04050709", "title": "QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "PD-L1 t-haNK", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-07-18", "completion_date": "2026-03-25", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04050709" }, { "nct_id": "NCT00021047", "title": "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Portsmouth, Virginia", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Portsmouth", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021047" }, { "nct_id": "NCT02152943", "title": "Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Estrogen Receptor Positive", "HER2/Neu Positive", "Postmenopausal", "Premenopausal", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Refractory Breast Carcinoma", "Refractory Hormone Receptor Positive Breast Carcinoma", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2014-07-17", "completion_date": "2020-12-14", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 5, "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Nassau Bay", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02152943" }, { "nct_id": "NCT02608125", "title": "A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter" ], "interventions": [ { "name": "PRN1371", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Principia Biopharma, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2015-10-28", "completion_date": "2020-06-23", "has_results": false, "last_update_posted_date": "2020-12-24", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 5, "location_summary": "San Francisco, California • Baltimore, Maryland • Winston-Salem, North Carolina + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02608125" }, { "nct_id": "NCT03037385", "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "RET-altered Non Small Cell Lung Cancer", "Medullary Thyroid Cancer", "RET-altered Papillary Thyroid Cancer", "RET-altered Colon Cancer", "RET-altered Solid Tumors", "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Thyroid Diseases", "Thyroid Neoplasm", "Thyroid Cancer, Papillary", "Carcinoma, Neuroendocrine", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Neoplasms by Site", "Neoplasms", "Lung Diseases", "Respiratory Tract Disease", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Endocrine System Diseases", "Endocrine Gland Neoplasm", "Head and Neck Neoplasms", "Adenocarcinoma, Papillary", "Adenocarcinoma", "Carcinoma", "Neoplasms, Glandular and Epithelial", "Neoplasms by Histologic Type", "Neuroendocrine Tumors", "Neuroectodermal Tumors", "Neoplasms, Germ Cell and Embryonal", "Neoplasms, Nerve Tissue", "Colonic Neoplasms", "Colorectal Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasm", "Digestive System Disease", "Gastrointestinal Disease", "Colonic Diseases", "Intestinal Disease" ], "interventions": [ { "name": "pralsetinib (BLU-667)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2017-03-17", "completion_date": "2024-03-21", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03037385" }, { "nct_id": "NCT01353625", "title": "Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Squamous Cell Carcinoma of Head and Neck", "Prostate Cancer", "Ewing's Osteosarcoma", "Chronic Lymphocytic Leukemia", "Neoplasm Metastasis" ], "interventions": [ { "name": "CC-115", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2011-04-25", "completion_date": "2021-03-12", "has_results": false, "last_update_posted_date": "2021-10-05", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01353625" }, { "nct_id": "NCT07339176", "title": "Intratumoral N17350 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms, Solid Tumor", "Breast Neoplasms, Triple-Negative", "Squamous Cell Carcinoma of Skin", "Melanoma", "Head and Neck Neoplasms", "Carcinoma, Squamous Cell", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "N17350", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Onchilles Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2026-05-25", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 6, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07339176" }, { "nct_id": "NCT06391918", "title": "Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "GEN2 + Valganciclovir", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GenVivo, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2024-03-04", "completion_date": "2026-03-01", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 7, "location_summary": "Duarte, California • Los Angeles, California • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06391918" }, { "nct_id": "NCT00004065", "title": "Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Colorectal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Kidney Cancer", "Leukemia", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Prostate Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 2, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004065" }, { "nct_id": "NCT00031967", "title": "Melatonin and Radiation Therapy in Treating Patients With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Radiation Toxicity", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "therapeutic melatonin", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "0 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-10-18T00:13:13.024Z", "location_count": 215, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031967" } ] }